论文部分内容阅读
近十余年来,由于抗白血病药物的不断问世,细胞增殖动力学研究结果的启发,治疗方法的改进与支持疗法的加强,急性白血病的疗效已明显提高。目前急淋儿童的完全缓解(CR)率已达90％,生存期超过五年以上者已达40～50％,超过十年者已达5～25％,并有少数病人得到了痊愈。但成人急性白血病,尤其是急性非淋巴细胞白血病(ANLL)的治疗,虽也有不少进展,但不论CR率抑或生存期都远不如急淋高,其CR率一般仅约50％左右,且即使获得CR,中数生存期亦仅约一至二年,生存期超过五年
In the recent ten years, due to the advent of anti-leukemia drugs, the research results of cell proliferation kinetics, the improvement of treatment methods and the strengthening of supportive therapy, the efficacy of acute leukemia has been significantly improved. At present, the rate of complete remission (CR) in acute children has reached 90%, and the survival rate has reached 40 to 50% for more than five years. After more than 10 years, the rate has reached 5 to 25%, and a few patients have been cured. However, although there have been many advances in the treatment of adult acute leukemia, especially acute non-lymphocytic leukemia (ANLL), the CR rate is generally only about 50% regardless of CR rate or survival rate CR, the median survival of only about one to two years, the survival of more than five years